4Brixius K , Reicke S , Schwinger RH , et al. Benificial effects of the Ca^2+ sensitizer levosinmendan in human myocardium[J]. Am J Physiol Heart Circ Physiol, 2002, 282(1) :131- 137.
5Szilayi S,Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts , myoeyte- sized preparations and phosphodiesterase enzymes of the guinea pig[J]. EurJ Pharmacol ,2004,486(1): 67-74.
6Paraskevaids IA, Parissis JT. Anti inflammatory and an- ti apottotic effcets of levosimendan in decompensated heart failure: a novel mechanism of drug-induced im- proved in contractile performance of the failing heart [J]. Curr Med chem Cardiovasc Hematol Agents, 2005,3(3) : 243 -247.
7Brixius K , Reicke S , Schwinger RH , et al. Benificial effects of the Ca^2+ sensitizer levosinmendan in human myocardium[J]. Am J Physiol Heart Circ Physiol, 2002, 282(1):131- 137.
8Antila S,Jarvinen A, Honkanen T, et al. Pharmacokinet-ic and pharmacodynamic interaction between the novel calcium sensitiser levosimendan and warfarin [J]. Eur J Clin Pharmacol, 2000,56 ( 9 -- 10) : 705-710.
10Matti D, Kivikko MD,Saila A,et al. Pharmacodynam- ics and safety of a new calcium sensitizer,levosimendan, and its metabolites during an extended infusion in patients with severe heart failure[J]. Clin Pharmacol, 2002,42 (1) :43- 51.
7Kaheinen P, PoUesello P, Levijoki J. Effects of levosimendan and milri- none on oxygen consumption in isolated guinea-pig heart[ J]. J Cardiovas Pharmaco1,2004 ;43 (4) :555-61.
8Kivikko M, Lehtonen L Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure [ J ]. Curr Phann Des, 2005 ; 11 (4) :435-55.
